Alexander Fulton
A5036809229- Advanced Breast Cancer Therapies
- PARP inhibition in cancer therapy
- Colorectal Cancer Screening and Detection
- Global Cancer Incidence and Screening
- Economic and Financial Impacts of Cancer
- Breast Cancer Treatment Studies
- Bioinformatics and Genomic Networks
- Cancer Genomics and Diagnostics
- BRCA gene mutations in cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- Lymphoma Diagnosis and Treatment
- Ubiquitin and proteasome pathways
Cancer Research UK Cambridge Center
2024-2025
University of Cambridge
2024-2025
The Christie NHS Foundation Trust
2020
PARTNER is a prospective, phase II-III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer
Abstract Data from clinical trials (CTs) drive advancements in practice. Despite most CTs now incorporating extensive translational portfolios, the diverse modalities of and sample data they generate often remain disconnected underutilised. SYNERGIA is a resource designed to integrate multi-modal multiple comparable format, that will be appropriately accessible clinicians researchers. The aims are to:1) Develop comprehensive, repository integrates longitudinal CT (>5 years), with...
Abstract Background: TNBCs in patients (pts) who are germline BRCA wild type (gBRCAwt) may show homologous recombination deficiency and genomic instability, resulting a BRCA-like phenotype. The PARTNER Trial tested olaparib combination with neoadjuvant carboplatin paclitaxel pts TNBC (gBRCAwt). Methods: Pts diagnosed locally were confirmed centrally immunohistochemistry for ER, PR, HER2 EGFR, CK5/6 AR to define basal-like TNBC, before entry the trial. gBRCAwt. Tumours assessed tumour...